{
    "title": "109_hr870",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Pharmaceutical Research and \nManufacturers Accountability Act of 2005'' or the ``PhRMA Act of \n2005''.\n\nSEC. 2. CONCEALMENT OF SERIOUS ADVERSE DRUG EXPERIENCE.\n\n    (a) Penalty for Knowing Concealment of Serious Adverse Drug \nExperience.--Section 303 of the Federal Food, Drug, and Cosmetic Act \n(21 U.S.C. 333) is amended by adding at the end the following:\n    ``(h) An individual who violates a provision of section 301 shall \nbe imprisoned for a term of a minimum of 20 years and a maximum of \nlife, fined not more than $2,000,000, or both, if--\n            ``(1) the individual is employed as the chief executive \n        officer or a member of the senior executive management group of \n        the manufacturer of a drug; and\n            ``(2) the violation involves, with respect to such drug, \n        knowing concealment by the individual of evidence of a serious \n        adverse drug experience (as that term is defined in section \n        505(o)).''.\n    (b) Annual Attestation by CEO Regarding Any Serious Adverse Drug \nExperience.--The Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et \nseq.) is amended--\n            (1) in section 505 (21 U.S.C. 355), by adding at the end \n        the following:\n    ``(o) Annual Attestation by CEO Regarding Any Serious Adverse Drug \nExperience.--\n            ``(1) Requirement.--For each drug for which an approval of \n        an application filed under subsection (b) or (j) is in effect, \n        the Secretary shall require the chief executive officer of the \n        manufacturer of the drug to submit a separate, written \n        attestation on an annual basis--\n                    ``(A) stating that the manufacturer has disclosed \n                to the Secretary all evidence of any serious adverse \n                drug experience related to the drug; and\n                    ``(B) describing the process by which the \n                manufacturer ensures that such disclosure has occurred.\n            ``(2) Definitions.--For purposes of this subsection:\n                    ``(A) The term `evidence of any serious adverse \n                drug experience' includes any evidence of a serious \n                adverse drug experience that--\n                            ``(i) is obtained by the manufacturer \n                        involved from any source of information, \n                        foreign or domestic, including any information \n                        obtained from a clinical trial conducted before \n                        or after approval of the drug, from \n                        postmarketing surveillance of the drug, or from \n                        a postmarketing report by a physician; or\n                            ``(ii) is required by any provision of this \n                        Act to be reported by the manufacturer to the \n                        Secretary.\n                    ``(B) The term `serious adverse drug experience' \n                means an adverse drug experience occurring at any dose \n                that results in--\n                            ``(i) death, a life-threatening adverse \n                        drug experience, inpatient hospitalization, \n                        prolongation of existing hospitalization, a \n                        persistent or significant disability or \n                        incapacity, or a congenital anomaly or birth \n                        defect; or\n                            ``(ii) a medical event that, based on \n                        appropriate medical judgment, may jeopardize \n                        the patient or subject and may require medical \n                        or surgical intervention to prevent one of the \n                        outcomes listed in clause (i).\n            ``(3) Initial attestation.--The Secretary shall require \n        that the first attestation under this subsection for a drug be \n        submitted--\n                    ``(A) in the case of a drug for which approval of \n                an application filed under subsection (b) or (j) is in \n                effect on the date of the enactment of this subsection, \n                not later than 1 year after such date; and\n                    ``(B) in the case of any other drug, not later than \n                1 year after the the date of such approval for the \n                drug.\n            ``(4) Failure to submit.--If the chief executive officer of \n        a manufacturer of a drug for which an approval of an \n        application filed under subsection (b) or (j) is in effect \n        fails to submit a timely attestation for the drug as required \n        by paragraph (1), the Secretary--\n                    ``(A) may issue an order withdrawing approval of \n                the application; and\n                    ``(B) shall not revoke such an order, or otherwise \n                approve or reinstate the application, unless--\n                            ``(i) the Secretary conducts a review of \n                        the drug's safety;\n                            ``(ii) the Secretary determines that the \n                        drug is safe for use; and\n                            ``(iii) the manufacturer reimburses the \n                        Secretary for the costs of such review and \n                        determination.\n            ``(5) Supplemental information.--In conducting a review \n        under paragraph (4)(B)(i), the Secretary may require the \n        manufacturer of the drug involved to submit supplemental \n        information on the drug's safety.'';\n            (2) in section 301 (21 U.S.C. 331), by inserting at the end \n        the following:\n    ``(hh) The failure to submit an attestation in accordance with \nsection 505(o).''; and\n            (3) in section 303 (21 U.S.C. 333), as amended by \n        subsection (a), by adding at the end the following:\n    ``(i)(1) A person who violates section 301(hh) by failing to submit \nan attestation in accordance with section 505(o) shall be fined--\n            ``(A) in the case of an individual, in accordance with \n        title 18, United States Code; and\n            ``(B) in the case of any other person, not more than \n        $1,000,000.\n    ``(2) Each 30-day period during which such violation continues \nshall constitute a separate offense.''.\n    (c) Deadline for Postmarketing Studies.--\n            (1) In general.--The Federal Food, Drug, and Cosmetic Act \n        (21 U.S.C. 301 et seq.) is amended--\n                    (A) in section 505 (21 U.S.C. 355), as amended by \n                subsection (b)(1), by adding at the end the following:\n    ``(p) Deadline for Postmarketing Studies of Drugs.--\n            ``(1) Requirement.--If the Secretary requires the \n        manufacturer or sponsor of a drug to conduct a postmaketing \n        study of the drug, the Secretary shall require the manufacturer \n        or sponsor to complete the study by a specified deadline.\n            ``(2) Extension.--On request, the Secretary may extend a \n        deadline established under this subsection.'';\n                    (B) in section 301 (21 U.S.C. 331), as amended by \n                subsection (b)(2), by inserting at the end the \n                following:\n    ``(ii) The failure to complete a postmarketing study by the \ndeadline established by the Secretary for such study under section \n505(p).''; and\n                    (C) in section 303 (21 U.S.C. 333), as amended by \n                subsections (a) and (b)(3), by adding at the end the \n                following:\n    ``(j) A person who violates section 301(ii) by failing to complete \na postmarketing study for a drug by the deadline established by the \nSecretary for such study under section 505(p) shall be fined not more \nthan $5,000,000. Each 30-day period during which such violation \ncontinues shall constitute a separate offense.''.\n            (2) Application.--The amendments made by this subsection \n        apply only with respect to a drug for which an application is \n        filed under subsection (b) or (j) of section 505 of the Federal \n        Food, Drug, and Cosmetic Act (21 U.S.C. 33) on or after the \n        date of the enactment of this Act.\n    (d) Prohibition Against Indemnification.--No person shall indemnify \nthe chief executive officer of a drug manufacturer or any other \nindividual for any fine incurred under the amendments made by this Act."
}